Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Advances Azenosertib in Ovarian Cancer with Pivotal Dose Selection and Phase 3 Initiation

Zentalis Pharmaceuticals announced its Q1 2026 financial results and significant clinical advancements for its WEE1 inhibitor, azenosertib. The company selected 400mg QD 5:2 as the pivotal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) based on DENALI Part 2a data, supporting an accelerated approval pathway. Concurrently, the Phase 3 ASPENOVA confirmatory trial was initiated with the first patient dosed, aiming for full approval and ex-US registrations. Zentalis reported $211.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a financial runway into late 2027 to support key milestones, including the DENALI Part 2 topline readout expected by year-end 2026.

• Pivotal Dose Selection for Azenosertib Monotherapy: Zentalis selected 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) as the pivotal study dose for azenosertib monotherapy in Cyclin E1-positive PROC. This decision was based on an interim analysis from DENALI Part 2a, which demonstrated a meaningful response rate and comparable safety, including a discontinuation rate due to adverse events at approximately half the rate reported in DENALI Part 1b.
• Initiation of ASPENOVA Phase 3 Confirmatory Trial: The first patient was dosed in the randomized, controlled Phase 3 ASPENOVA trial, designed to enroll approximately 420 patients. This trial compares azenosertib monotherapy (400mg QD 5:2) against investigator's choice of standard-of-care chemotherapy in Cyclin E1-positive PROC patients. ASPENOVA aims to support conversion to full FDA approval and facilitate ex-US registrations following a potential accelerated approval from DENALI Part 2.
• Strong Financial Position and Clinical Milestones: Zentalis reported a robust cash position of $211.8 million as of March 31, 2026, which is projected to fund operations into late 2027. This financial stability supports the execution of critical upcoming milestones, most notably the anticipated topline readout from the DENALI Part 2 trial by year-end 2026, which is designed to support a potential accelerated approval pathway.

DENALI's Pivotal Dose Selection and Accelerated Approval Pathway

The clinical development of treatments for Cyclin E1-positive platinum-resistant ovarian cancer has been explored across multiple therapeutic approaches, with varying study designs targeting this challenging patient population. Key trials have evaluated ATR inhibition, Wee1 inhibition, and combination therapies, providing insights into both efficacy outcomes and biomarker-driven patient selection strategies.

• SCOTROC4 biomarker analysis (2019) evaluated CCNE1 copy-number variation in 250 ovarian tumors (179 high-grade serous subgroup) treated with carboplatin monotherapy, defining CCNE1 amplification positive as CNV score >2.4, with primary endpoints of CA125 complete response and secondary endpoints of progression-free survival and overall survival

• Gemcitabine plus berzosertib phase II trial (2020) enrolled 70 women aged ≥18 years with recurrent, platinum-resistant high-grade serous ovarian cancer, randomized 1:1 to gemcitabine alone versus gemcitabine plus berzosertib (ATR inhibitor), with primary endpoint of progression-free survival and secondary endpoints including safety and tolerability

• ADAGIO phase IIb study (2025) was a single-arm, multicenter trial (NCT04590248) of adavosertib (Wee1 inhibitor) in 104 evaluable patients with recurrent/persistent uterine serous carcinoma previously treated with platinum-based chemotherapy, with primary endpoint of objective response rate by blinded independent central review and secondary endpoints of duration of response, progression-free survival, and biomarker assessment

• Adavosertib monotherapy trial (2023) treated 80 patients with triple-negative breast cancer using oral adavosertib 175 mg twice daily on days 1-3 and 8-10 of 21-day cycles, with efficacy endpoints stratified by CCNE1/MYC/MYCL1/MYCN biomarker amplification status and safety as primary considerations

• Olaparib/onalespib combination study (2022) was a dose-escalation trial evaluating PARP inhibitor plus HSP90 inhibitor combination therapy, with dose levels up to olaparib 300 mg/onalespib 40 mg, measuring objective response rates and disease stabilization ≥24 weeks as primary efficacy endpoints in patients with RB-pathway alterations including CCNE1 overexpression

Expanding Azenosertib's Reach Beyond Platinum-Resistant Ovarian Cancer

Azenosertib (ZN-c3) is expanding beyond its initial ovarian cancer focus into broader oncology applications. Phase I studies with azenosertib as monotherapy have demonstrated preliminary clinical activity in patients with advanced solid tumors, supporting further investigation across multiple tumor types.

• Advanced solid tumors: Azenosertib is being evaluated as monotherapy in patients with advanced solid tumors refractory to standard therapy or for which no standard of care exists

• KRASG12C inhibitor-resistant tumors: Preclinical data shows synergistic interactions between azenosertib and multiple KRASG12C inhibitors, potentially leading to deeper and more durable responses in resistant cases

• Broad tumor model applications: Preclinical studies demonstrate robust tumor growth inhibition across a wide range of tumor models, with optimized pharmacokinetic and pharmacodynamic properties

• Dosing schedule optimization: Various dosing regimens have been explored in preclinical efficacy models to preserve antitumor activity while minimizing toxicity

• Delayed tumor regrowth applications: Azenosertib shows high effectiveness at delaying tumor regrowth duration after treatment cessation, suggesting potential for maintenance therapy approaches

Azenosertib's Pivotal Leap in Cyclin E1-Positive Ovarian Cancer

The latest update from Zentalis Pharmaceuticals signals a pivotal moment for patients battling Cyclin E1-positive platinum-resistant ovarian cancer, an area of significant unmet need. By advancing azenosertib, a WEE1 inhibitor, into a pivotal monotherapy study with a clear path towards accelerated approval, the company is leveraging a precision medicine approach that targets a specific molecular vulnerability. Research indicates that WEE1 kinase plays a critical role in regulating the G2/M checkpoint, and its inhibition can induce genomic instability, particularly in cancers with G1/S checkpoint deficiencies like ovarian cancer, which often harbor TP53 mutations. The identification of Cyclin E1 amplification or high expression as a biomarker for sensitivity to WEE1 inhibitors further refines this strategy, promising a more targeted and potentially effective treatment.

This strategic move, supported by a robust financial position, could see azenosertib reach patients sooner, establishing a significant foothold in a challenging therapeutic landscape. However, the journey is not without its complexities. While WEE1 inhibition shows promise, studies have revealed mechanisms of adaptive resistance, such as the activation of the mTOR pathway or ROR1-PI3K/AKT signaling, which could necessitate future combination therapies to sustain efficacy. Furthermore, the known toxicities associated with WEE1 inhibitors, including myelosuppression and gastrointestinal effects, will require careful management to ensure patient quality of life and adherence. The broader context of drug development in late-line ovarian cancer also presents a cautionary tale, as evidenced by the recent withdrawal of PARP inhibitors from this setting due to overall survival concerns. This underscores the high bar for demonstrating durable benefit and favorable risk-benefit in this patient population. Ultimately, the success of azenosertib will hinge on its ability to deliver sustained clinical benefit while managing these inherent challenges, potentially reshaping the treatment paradigm for this aggressive form of ovarian cancer.